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Summary
 Background—For second-line antiretroviral therapy, WHO recommends a boosted protease 
inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs). However, concerns 
about toxicity and cross-resistance motivated a search for regimens that do not contain NRTIs. We 
aimed to assess whether boosted lopinavir plus raltegravir would be non-inferior to boosted 
lopinavir plus NRTIs for virological suppression in resource-limited settings.
 Methods—A5273 was a randomised, open-label, phase 3, non-inferiority study at 15 AIDS 
Clinical Trials Group (ACTG) research sites in nine resource-limited countries (three sites each in 
India and South Africa, two each in Malawi and Peru, and one each in Brazil, Kenya, Tanzania, 
Thailand, and Zimbabwe). Adults with plasma HIV-1 RNA concentrations of at least 1000 copies 
per mL after at least 24 weeks on a regimen based on a non-NRTI inhibitor were randomly 
assigned (1:1) to receive oral ritonavir-boosted lopinavir (100 mg ritonavir, 400 mg lopinavir) plus 
400 mg raltegravir twice a day (raltegravir group) or to ritonavir-boosted lopinavir plus two or 
three NRTIs selected from an algorithm (eg, zidovudine after failure with tenofovir and vice versa; 
NRTI group). Randomised group assignment was done with a computer algorithm concealed to 
site personnel, and stratified by HIV-1 RNA viral load, CD4 cell count, and intention to use 
zidovudine, with the groups balanced by each site. The primary endpoint was time to confirmed 
virological failure (two measurements of HIV-1 RNA viral load >400 copies per mL) at or after 
week 24 in the intention-to-treat population. Non-inferiority (10% margin) was assessed by 
comparing the cumulative probability of virological failure by 48 weeks. This trial was registered 
with ClinicalTrials.gov, NCT01352715.
 Findings—Between March 13, 2012, and Oct 2, 2013, we randomly assigned 515 participants: 
260 to the raltegravir group and 255 to the NRTI group; two participants in the raltegravir group 
and one in the NRTI group were excluded from analyses because of ineligibility. By the end of 
follow-up (October, 2014), 96 participants had virological failure (46 in the raltegravir group and 
50 in the NRTI group). By 48 weeks, the cumulative probability of virological failure was 10·3% 
(95% CI 6·5–14·0) in the raltegravir group and 12·4% (8·3–16·5) in the NRTI group, with a 
weighted difference of −3·4% (−8·4 to 1·5), indicating that raltegravir was non-inferior, but not 
superior, to NRTIs. 62 (24%) participants in the raltegravir group and 81 (32%) in the NRTI group 
had grade 3 or higher adverse events; 19 (7%) and 29 (11%), respectively, had serious adverse 
events. Three participants in each group died, all from HIV-related causes.
 Interpretation—In settings with extensive NRTI resistance but no available resistance testing, 
our data support WHO’s recommendation for ritonavir-boosted lopinavir plus NRTI for second-
line antiretroviral therapy. Ritonavir-boosted lopinavir plus raltegravir is an appropriate alternative, 
especially if NRTI use is limited by toxicity.
 Funding—National Institutes of Health.
 Introduction
Suppression of HIV replication with combination antiretroviral therapy decreases morbidity 
and mortality in people with HIV.1 As of June, 2015, about 37 million people were living 
with HIV, most of them in resource-limited settings, and an estimated 15 million people 
were on antiretroviral therapy.2 With increasing evidence about the benefits of antiretroviral 
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therapy for all, WHO is recommending that all people with HIV should receive antiretroviral 
therapy.3,4 Treatment failure has been reported to occur in about 20% of individuals 
receiving first-line antiretroviral therapy in a range of resource-limited settings, suggesting 
that the need for second-line antiretroviral therapy will continue to grow.5,6 In 2015, more 
than 500 000 people in resource-limited settings received second-line antiretroviral therapy; 
a number that WHO is projecting will steadily increase over the next 10 years.7
WHO recommends a regimen of a ritonavir-boosted protease inhibitor plus two nucleoside 
or nucleotide reverse transcriptase inhibitors (NRTIs) for second-line treatment. However, 
concerns that retaining NRTI in second-line regimens could lead to cumulative toxicity or 
lower efficacy due to cross-resistance have motivated three large international randomised 
studies of NRTI-sparing antiretroviral therapy consisting of ritonavir-boosted lopinavir plus 
raltegravir, an inhibitor of HIV integrase. Results of two of these studies have been 
published.8–10 EARNEST was an open-label trial in sub-Saharan Africa that aimed to 
recapitulate a public health approach by using clinician-selected NRTIs without resistance 
testing and a primary composite endpoint of good HIV disease control.8 SECOND-LINE 
was done in mainly middle-income and high-income countries, 73% of the participants had 
study entry resistance testing, and the study had a primary endpoint of HIV suppression 
lower than 200 copies per mL.9,10 Both trials found the efficacy and safety of ritonavir-
boosted lopinavir plus raltegravir to be largely similar to ritonavir-boosted lopinavir plus 
NRTIs. These findings validated both WHO’s and NRTI-sparing approaches, but the authors 
emphasised different interpretations, perhaps reflecting the availability of resources in their 
settings. The investigators for EARNEST concluded that there was no advantage to 
replacing NRTIs with raltegravir, whereas those for SECOND-LINE concluded that the 
ritonavir-boosted lopinavir plus raltegravir provided a simple, effective, safe, and tolerable 
second-line antiretroviral therapy.
 Methods
 Study design and participants
A5273 was a randomised, phase 3, open-label, non-inferiority study of second-line 
antiretroviral therapy at 15 ACTG research sites in South Africa and India (three centres 
each), Malawi and Peru (two each), and Zimbabwe, Kenya, Tanzania, Thailand, and Brazil. 
11 sites provided access to research and primary, secondary, or tertiary medical care and four 
sites were dedicated research sites. We recruited clinically stable, HIV-1-infected adults (≥18 
years) who had confirmed plasma HIV-1 RNA concentrations of 1000 copies per mL or 
higher (two consecutive measurements at least 1 week apart) after at least 24 weeks on an 
initial regimen containing a non-nucleoside reverse transcriptase inhibitor. The first RNA 
concentration could be obtained from medical records up to 90 days before study entry. The 
second measurement had to be obtained within 45 days before study entry and done in a 
Division of AIDS (DAIDS)-approved laboratory.
Entry criteria are listed in the protocol. Exclusion criteria included previous exposure to 
protease inhibitors and known broad NRTI resistance (defined as participants with resistance 
patterns that, in the investigators opinion, would not allow selection of an effective NRTI 
combination). Prospective resistance testing was not done as part of the study and was not 
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routinely done at study sites to manage first-line antiretroviral therapy failure. Other 
exclusion criteria included pregnancy, active hepatitis B infection, and tuberculosis needing 
rifampicin treatment (because of adverse drug interactions with ritonavir). HLA-B*5701 
testing followed local standard of care and was not done as part of the study. The study was 
approved by ethics committees at each site and written informed consent was obtained from 
each participant.
 Procedures
Participants were assigned to receive either oral ritonavir-boosted lopinavir (100 mg 
ritonavir, 400 mg lopinavir; Abbott Laboratories; Abbott Park, IL, USA) plus 400 mg 
raltegravir (Merck Sharp & Dohme; North Wales, PA, USA) twice a day (raltegravir group), 
or ritonavir-boosted lopinavir (same dose as above) plus the best available two or three 
NRTIs selected by the site investigator before randomisation from an algorithm approved by 
the study team (NRTI group). For the NRTI group, if tenofovir disoproxil fumarate was not 
included in the participant’s first-line regimen then emtricitabine plus tenofovir disoproxil 
fumarate or emtricitabine, tenofovir disoproxil fumarate, plus zidovudine were preferred. If 
tenofovir disoproxil fumarate was included in the first-line regimen then lamivudine plus 
zidovudine or emtricitabine, tenofovir disoproxil fumarate, plus zidovudine were preferred. 
Acceptable alternative NRTI combinations were predefined and included two-drug or three-
drug combinations of zidovudine, lamivudine or emtricitabine, abacavir, and tenofovir 
disoproxil fumarate. NRTIs provided by the study were fixed-dose combination 200 mg 
emtricitabine and 300 mg tenofovir disoproxil fumarate (Gilead Sciences; Foster City, CA, 
USA), and the following fixed-dose combinations and drugs from GlaxoSmithKline 
(Uxbridge, Middlesex, UK): 300 mg abacavir, 150 mg lamivudine, and 300 mg zidovudine; 
300 mg abacavir and 150 mg lamivudine; 600 mg abacavir and 300 mg lamivudine; 150 mg 
lamivudine and 300 mg zidovudine; 300 mg abacavir; 600 mg abacavir; 150 mg lamivudine; 
300 mg lamivudine; and 300 mg zidovudine. Other locally provided, US Food and Drug 
Administration (FDA)-prequalified, NRTIs could be used with the approval of the study 
team. NRTI substitutions due to intolerance were allowed. Substitution of ritonavir-boosted 
lopinavir or raltegravir was not allowed.
Participants entered the study and were randomly assigned treatment within 45 days of 
screening. Subsequent on-study investigations occurred at weeks 4, 12, and 24 after entry, 
and every 12 weeks thereafter. Each participant was followed up until week 96 or 52 weeks 
after the last participant was enrolled, whichever was earliest. Visits included clinical and 
laboratory assessments (plasma HIV-1 RNA viral load, CD4 cell counts, complete blood 
counts, and comprehensive chemistry and lipid panels) and assessment for disease 
complications and adverse drug effects. Adherence counselling was done by site staff 
members at study entry according to each site’s standard of care, at any visit deemed 
necessary by the site, and during the follow-up visit after virological failure. At study entry 
and at weeks 4, 24, 48, 72, and 96, an adherence questionnaire11 was completed by the 
participant or with the assistance of the study coordinator. Laboratory testing was completed 
in DAIDS-approved laboratories. Site staff and investigators graded signs, symptoms, and 
laboratory events according to the DAIDS Toxicity Scale (version 1.0);12 they received 
training on recognition and management of abacavir hypersensitivity. AIDS-defining 
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illnesses were those accepted by the Centers for Disease Control and WHO.13,14 Serious 
non-AIDS diagnoses (based on ACTG appendix 60 diagnostic codes15) were adjudicated by 
the study Co-chairs, one Vice-chair, and a Co-investigator masked to study treatment; a 
minimum of two people in the adjudication group had to agree with the designation, and 
disagreements were resolved by discussion with other people in the adjudication group. 
Serious non-AIDS events were those that required hospitalisation or were medically severe.
We measured plasma HIV-1 RNA after the first screening test using the Abbott HIV-1 
RealTime assay (Abbott Laboratories) at laboratories certified by the DAIDS Virology 
quality assurance programme. An independent reviewer masked to study treatment 
adjudicated decisions on virological failure. Full-length reverse transcriptase (codons 1–560) 
and protease (codons 1–99) genotyping with a quality assurance programme-certified assay 
was done at the University of Pittsburgh (PA, USA) and the Lancet Laboratory 
(Johannesburg, South Africa) on stored samples from study entry for all participants and on 
confirmation samples for participants with study-defined virological failure. Integrase 
(codons 11–288) genotyping was done on paired samples from study entry and virological 
failure. Major mutations were defined according to the International Antiviral Society (IAS) 
USA July, 2014, list and susceptibility scores according to the Stanford algorithm version 
7.0.16,17
 Randomisation and masking
We used a computer algorithm at the ACTG’s Statistical and Data Management Center to 
randomly assign participants (1:1) to receive ritonavir-boosted lopinavir plus raltegravir or 
ritonavir-boosted lopinavir plus NRTI. Randomisation was stratified by screening plasma 
HIV-1 RNA viral load (<100 000 copies per mL or ≥100 000 copies per mL), CD4 count 
(<100 cells per μL or ≥100 cells per μL), and intention to use zidovudine (if subsequently 
assigned to receive NRTI) with use of permuted blocks with a block size of four. The 
algorithm tracked previous allocations by site; if a preset threshold for imbalance was 
reached, then the computer allocated the next participant at that site to the group with fewer 
allocations. Site personnel completed online checklists to confirm eligibility before group 
allocation and had access to the participant’s allocation details only once these checklists 
were complete. The study team was masked to the randomisation details and laboratory 
personnel who ran the viral load assays were masked to treatment allocation. The 
independent investigator who confirmed the primary outcome was masked to treatment 
assignment. Participants and other site personnel were not masked to group allocation.
 Outcomes
The prespecified primary endpoint was time to virological failure defined as two consecutive 
plasma HIV-1 RNA viral load measurements higher than 400 copies per mL at or after week 
24, irrespective of the time between the two measurements. For participants who 
discontinued the study for any reason, a final viral load was recorded as virological failure if 
more than 400 copies per mL and less than 0·5 log10 lower than baseline at week 4; more 
than 400 copies per mL and less than 1 log10 lower than baseline at week 12; and un 
confirmed concentration of more than 400 copies per mL as of that study week at or after 
week 24. Sites were instructed to schedule a confirmatory sample drawn at least 1 week after 
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the initial test showing a viral load higher than 400 copies per mL and, if possible, no later 
than the next scheduled study visit and before the end of study participation. Prespecified 
secondary endpoints were change in CD4 cell count; new drug-resistance mutations; time to 
first grade 3 or higher adverse event; time to discontinuation of randomised treatment for 
toxicity; time to new AIDS-defining event, death, and targeted serious non-AIDS event; 
incidence and duration of hospitalisations; and change in fasting lipid concentrations. 
Additional supportive exploratory endpoints were time to virological failure or earliest 
treatment discontinuation; HIV-1 RNA concentrations of 400 copies per mL or lower; and 
liver function tests. We also assessed self-reported adherence.
 Statistical analysis
Sample size was based on assessing non-inferiority of the raltegravir arm compared with the 
NRTI arm at a prespecified margin of 10% with a one-sided 2·5% type I error rate. The 
analysis plan included assessment for raltegravir arm superiority (upper bound of the CI 
<0%) if non-inferiority was found. When the study was designed, no published results were 
available from randomised trials of ritonavir-boosted lopinavir and raltegravir. We estimated 
the sample size based on estimates from other antiretroviral studies and the opinion of the 
study team. The target sample size of 600 participants (300 per group) was based on 
assumed virological failure of 25% in the raltegravir group and 28% in the NRTI group, and 
would provide at least 90% power for the comparison of the primary endpoint. Sample size 
was re-evaluated on Aug 7, 2013, due to availability of data from other international studies 
of second-line therapy,8,9,18 and the ACTG made a decision about revising the protocol 
enrolment and follow-up that was communicated to the core team on Aug 22, 2013, and the 
study sites on Aug 28, 2013, and followed by a protocol amendment. These data updated the 
assumptions of virological failure to 15% for the raltegravir group and 18% for the NRTI 
group, which provided the study with at least 90% power with a sample size of 480 
participants (240 per group).
Baseline values were the closest measurement at or before study entry but after screening. 
During follow-up, non-overlapping visit windows and measurements closest to each 
window’s centre were used. Participants were considered to have completed the protocol if 
they had a week 96 visit or a visit within the study closeout period. Discontinuation of 
randomised treatment was defined as permanent discontinuation of raltegravir, ritonavir-
boosted lopinavir, or NRTI, or intentional addition of two or more NRTIs without study 
NRTI discontinuation. Efficacy analyses used an intention-to-treat approach, censoring 
participants at their last visit. In the primary analysis (comparison between groups of the 
cumulative probability of virological failure by week 48) we used the Kaplan-Meier method 
with Greenwood’s variance weighted by randomisation stratification factors.19 More 
specifically, inference regarding non-inferiority was based on the differences in the 48 week 
cumulative incidence of virological failure with 95% CIs stratified by randomisation 
stratification factors. The inverse of the stratum-specific variance was used for the stratum 
weights.20 Subgroup analyses for the primary endpoint were prespecified for the 
randomisation stratification factors, sex, race (black vs non-black), country, HIV-1 subtype, 
and drug resistance at study entry; two-way interactions were evaluated based on the Wald 
test. Comparison of secondary endpoints between the study groups used stratified t test for 
La Rosa et al. Page 6
Lancet HIV. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
continuous outcomes, stratified log-rank test for time-to-event out comes, and stratified 
Cochran-Mantel-Haenszel (CMH) test for binary outcomes. Safety analyses used an as-
treated approach, censoring participants at the earlier of dis continuation of randomised 
treatment or their last contact.
To estimate activity of the selected NRTIs for each participant randomised to the NRTI 
group, we calculated an NRTI genotypic sensitivity score (GSS) by assigning each NRTI in 
the second-line regimen a score of 0, 0·25, 0·5, 0·75, or 1 for high-level, intermediate, low-
level, potential low-level resistance, or susceptibility, respectively, based on Stanford 
algorithm version 7.0, and summing these scores to give a maximum of 2 or 3, depending on 
the number of NRTIs in the regimen. The study was monitored by a data and safety 
monitoring board convened by the National Institute of Allergy and Infectious Diseases; as 
prespecified, they met twice during the study. We used SAS version 9.2 for all statistical 
analyses. The trial was registered with ClinicalTrials.gov, number NCT01352715.
 Role of the funding source
The funders of the study had an oversight role in the development and monitoring of the 
study but had no role in the conduct, analyses, and conclusions of the study. PK, an author of 
this study and a medical monitor from NIH/NIAID, had a role in the design, data 
interpretation, manuscript revision, and intellectual contribution; however, his views were 
his own and did not represent the funder’s views. The corresponding author had full access 
to all the data in the study and had final responsibility for the decision to submit for 
publication.
 Results
Between March 13, 2012, and Oct 2, 2013, we enrolled and randomly assigned 515 
participants (figure 1). Of the 82 participants who prematurely discontinued the study, 31 
were at sites unable to continue study participation due to loss of their ACTG network 
affiliation. 12 (2%) participants discontinued the study before week 48. 23 (4%) 
discontinued study therapy prematurely. Median follow-up was 87 weeks (IQR 71–96) and 
this did not differ by groups (85 weeks [70–96] in raltegravir group vs 88 [71–96] in NRTI 
group; Wilcoxon rank-sum p=0·84). The study closeout period was from Sept 17 to Oct 29, 
2014.
Characteristics at study entry were balanced between groups (table 1). Antiretroviral therapy 
exposure was similar between study groups with a median duration of first-line NNRTI-
containing triple antiretroviral therapy regimen of 4·0 years (IQR 2·2–6·1); 4·1 years (2·2–
6·3) in the raltegravir group and 4·0 years (2·2–6·0) in the NRTI group. The last NNRTI-
containing regimen before enrolment was lamivudine, zidovudine, and nevirapine for 124 
(24%) participants; lamivudine, tenofovir disoproxil fumarate, and efavirenz for 122 (24%); 
stavudine, lamivudine, and nevirapine for 109 (21%); lamivudine, tenofovir disoproxil 
fumarate, and nevirapine for 61 (12%); lamivudine, zidovudine, and efavirenz for 56 (11%); 
and other combinations for the remaining 40 (8%). Only 19 (4%) participants had locally 
provided resistance test results available at time of study entry. Emtricitabine and tenofovir 
disoproxil fumarate was chosen for most (n=173; 68%) of participants in the NRTI group.
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490 (96%) participants had full protease and reverse transcriptase sequences available from 
study entry (table 1). Overall, 96% had at least one NRTI mutation, 97% had at least one 
NNRTI mutation, and 95% had both. Most participants had extensive resistance (table 1). 
Except for the four participants with 69 insertion detected only in the NRTI group, resistance 
at study entry seemed similar between groups. The median NRTI GSS in the NRTI group 
was 1·00 (IQR 0·25–1·00; range 0–2). Major protease inhibitor mutations were rare; none 
were expected to affect susceptibility to ritonavir-boosted lopinavir.
By week 48, the cumulative probability of virological failure was 10·3% (95% CI 6·5–14·0) 
in the raltegravir group and 12·4% (8·3–16·5) in the NRTI group (figure 2). The primary 
analysis weighted by randomisation stratification factors showed a small difference of 
−3·4% (95% CI −8·4 to 1·5) favouring raltegravir and indicating non-inferiority, but not 
superiority, to NRTIs.
At week 48, 92% (95% CI 87–95) of participants in the raltegravir group and 91% (87–95) 
in the NRTI group had plasma HIV-1 RNA concentrations lower than 400 copies per mL 
(missing data ignored; stratified CMH p=0·91). The increase in CD4 count was 199 (95% CI 
181–218) in the raltegravir group and 190 (171–209) in the NRTI group. The mean increase 
in CD4 count from study entry to week 48 was 195 cells per μL (182–208), with no 
difference between groups (weighted t test p=0·33).
Cumulative probability of a composite of virological failure or discontinuation of 
randomised study treatment showed a similar result as our findings for the primary endpoint 
(difference of −3·4%, 95% CI −8·6 to 1·7). Additionally, analyses treating missing data as 
failure (like an FDA snapshot analysis) and only including those on randomised study 
treatment gave similar results (data not shown). Post-hoc analyses at weeks 24, 48, and 96 
using thresholds of 200 copies per mL and 40 copies per mL were consistent with the 
primary analysis (data not shown).
We observed no difference between the probability of virological failure between groups by 
any of the stratification factors (figure 3). A strong inverse association was detected between 
extent of NRTI resistance at study entry, as measured by multiple prespecified criteria, and 
probability of virological failure by 48 weeks. In the NRTI group, participants with a GSS of 
less than 1 (more resistance) had a lower probability of virological failure than did those 
with GSS of 1 or more (difference –8·4%, 95% CI –16·6 to –0·3; p=0·042). Similarly, having 
three or more IAS NRTI mutations was associated with a lower probability of virological 
failure in both groups (hazard ratio [HR] 0·45, 95% CI 0·30–0·70; p=0·00031). Also, having 
complex resistance at study entry (Lys65Arg, ≥3 thymidine analogue mutations [TAM], 
Gln151Met, or 69 insertion/deletion) was associated with lower probability of virological 
failure in both groups (HR 0·49, 95% CI 0·31–0·76; p=0·0013). Finally, presence of 
Met184Val/Ile at study entry was associated with a lower risk of virological failure 
compared to absence of Met184Val/Ile (0·41, 0·25–0·67; p=0·0004) and presence of both 
Lys65Arg and Met184Val/Ile at entry was associated with even lower risk of virological 
failure (0·19, 0·08–0·44; p=0·0001). These associations remained after adjustment for 
multiple confounding factors (baseline HIV-1 RNA concentration, week 4 self-reported 
adherence, first-line NRTI exposure, and country).
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Of the 96 participants (46 in the raltegravir group, 50 in the NRTI group) who had 
virological failure by the end of follow-up (Oct 27, 2014), paired study entry and failure 
samples were available for genotype analysis for 88% (table 2). 13 (29%) of 45 participants 
with available samples in the NRTI group developed new resistance mutations. Ten (26%) of 
39 in raltegravir group developed new resistance mutations, including integrase mutations in 
all ten, with Asn155His being most frequent.
Self-reported adherence was similar by randomised group at each visit overall and among 
those with virological failure. Self-reported adherence decreased over time, with 399 (78%) 
of 509, 352 (72%) of 490, and 147 (62%) of 237 of participants reporting never skipping 
medications at weeks 4, 48, and 96, respectively. Adherence was the lowest in participants 
with virological failure, with only 53% reporting never skipping antiretroviral therapy.
Three (1%) participants in each group prematurely discontinued randomised study treatment 
due to toxic effects and 21 (8%) in the NRTI group substituted one or more NRTIs. Grade 3 
or higher signs and symptoms and grade 3 or higher neurological events of many types 
occurred (table 3), with grade 3 or higher laboratory abnormalities found in more than a 
quarter of participants. More chemistry and haematological abnormalities occurred in the 
NRTI group than the raltegravir group; but more metabolic abnormalities occurred in the 
raltegravir group, mostly in LDL and total cholesterol. At week 48, the mean difference 
between groups for total cholesterol was 15·4 mg/dL (95% CI 8·3–22·6; p<0·0001), for LDL 
cholesterol was 7·9 mg/dL (2·0–13·8; p=0·0088), and for triglycerides was 43·6 mg/dL 
(18·2–69·1; p=0·0078). Time to first grade 3 or higher adverse event at least one grade 
higher than at study entry was shorter in the NRTI group than in the raltegravir group 
(stratified log-rank p=0·040; figure 4).
Three participants in each group died; all deaths occurred in participants starting the study 
with CD4 cell counts lower than 50 cells per μL (table 3). 27 new AIDS-defining diagnoses 
occurred in 26 (5%) participants with no difference by group (stratified log-rank p=0·66). 
Tuberculosis was the most commonly reported AIDS-defining diagnosis (n=20). 11 new 
serious non-AIDS diagnoses occurred in ten (2%) participants with no difference by group 
(stratified log-rank p=0·95); the most common was bacterial sepsis (table 3). Incidence of 
hospitalisation and total hospital days did not significantly differ by group (9% in the NRTI 
group and 6% in the raltegravir group). 48 (9%) participants had at least one serious adverse 
event: 29 (11%) in the NRTI group and and 19 (7%) in the raltegravir group. Five women in 
each group became pregnant.
 Discussion
Our findings from nine resource-limited countries show that both NRTIs and raltegravir, 
when added to ritonavir-boosted lopinavir, provide high virological efficacy with more than 
90% of participants having HIV-1 RNA concentrations lower than 400 copies per mL at 
week 48. Our primary analysis showed raltegravir to be non-inferior, but not superior to, 
NRTI therapy. Immunological response was robust in both groups with a mean increase of 
195 CD4 cells per mL gained from study entry to week 48.
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The virological suppression rate in the NRTI group is particularly impressive given the high 
prevalence of resistance at study entry to NRTIs (table 1) and the selection of NRTIs without 
aid of resistance testing in 96% of participants. Although the study’s NRTI selection 
algorithm recommended zidovudine for participants who had virological failure with 
tenofovir disoproxil fumarate and vice versa (to take advantage of the antagonistic pathways 
for thymidine analogues and tenofovir resistance),21 most participants had only one (range 
zero to two) active NRTI in their regimen and only a few (21%) were prescribed zidovudine. 
Overall, efficacy of the NRTI group was not compromised by extensive resistance at study 
entry and did not increase with more active NRTIs in the regimen. In fact, we observed a 
strong inverse association between the extent of NRTI resistance at study entry and 
probability of virological failure; a finding that was consistent in multiple analyses with 
different measures to quantify NRTI resistance including NRTI GSS (<1 vs >1), number of 
IAS NRTI mutations (>3 vs <3), or complex NRTI resistance (presence vs absence of 
Lys65Arg, ≥3 TAMs, Gln151Met, or 69 insertion/deletion). An inverse association between 
NRTI resistance and probability of virological failure was also reported by the SECOND-
LINE22 and EARNEST23 trials.
Our results confirm that ritonavir-boosted lopinavir provides substantial activity in second-
line antiretroviral therapy.24 Additional virological activity might be attributable to NRTIs, 
either as partly active drugs despite genotypical evidence of resistance or possibly by 
maintaining reduced viral fitness. Lys65Arg and Met184Val/Ile reduce replication capacity 
and their effects might be additive.25 Consistent with this, participants with Lys65Arg and 
Met184Val/Ile at study entry had a lower hazard of virological failure compared with 
participants with no Met184Val/Ile or with Met184Val/Ile alone. We hypothesise that 
resistance that arose during first-line therapy could have rendered the virus hypersusceptible 
to protease inhibitors and might partly explain the favourable response, despite extensive 
NRTI resistance, as well as to the raltegravir group that included ritonavir-boosted lopinavir 
in the regimen. This possibility is being investigated. Phenotypic hyper susceptibility to 
lopinavir or ritonavir and other protease inhibitors has been described in association with 
reduced replication capacity in viral isolates with wild-type protease.26
The inverse association between resistance at study entry and virological failure on second-
line antiretroviral therapy could also be explained if limited resistance is a marker of non-
adherence during first-line antiretroviral therapy that continued during second-line 
antiretroviral therapy. Participants with virological failure in this study had low self-reported 
adherence, suggesting that suboptimal adherence was likely a major contributor to 
virological failure. Similar to other clinical trials of boosted protease inhibitors, major 
lopinavir resistance mutations were rarely detected during virological failure. However, 
mutations in gag or gp41 of envelope have been reported to affect susceptibility to protease 
inhibitor in the absence of protease inhibitor mutations.27 To investigate this possibility, 
genotypic analyses of gag and env comparing entry and virological failure samples are in 
progress.
Similar proportions of participants with virological failure in each group had newly detected 
mutations, but the raltegravir group more frequently had integrase mutations whereas the 
NRTI group had either protease inhibitor or NRTI mutations (table 2). Which resistance 
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patterns will be less challenging to treat depends on availability of specific antiretroviral 
agents and strategies for regimen sequencing.
Two other large international randomised clinical trials have previously reported efficacy 
findings similar to ours.8–10 SECOND-LINE, in middle-income to high-income countries, 
found virological efficacy of ritonavir-boosted lopinavir plus raltegravir to be non-inferior to 
that of ritonavir-boosted lopinavir plus NRTIs, with about 82% and 75% of participants 
maintaining HIV-1 RNA concentrations lower than 200 copies per mL at 48 weeks and 96 
weeks, respectively. EARNEST was done in five low-income sub-Saharan African countries 
and although it used a composite clinical and laboratory primary endpoint, 86% of 
participants in both groups had HIV-1 RNA viral loads less than 400 copies per mL at 96 
weeks. In both studies, significant NRTI resistance at entry was found; however, the 
raltegravir group was non-inferior to the NRTI group. Although the efficacy results were 
similar in these studies of second-line antiretroviral therapy, ours include data from nine 
low-income and middle-income countries on three continents.
Significant, albeit modest, increases in concentrations of total cholesterol, LDL cholesterol, 
and triglycerides were noted in the raltegravir group (table 3). We observed no differences in 
HDL cholesterol or total:HDL cholesterol ratio (data not shown). These observations partly 
reflect the previously reported lipid-lowering effect of tenofovir disoproxil fumarate.28,29 
SECOND-LINE showed similar differences for total and LDL cholesterol.9 EARNEST did 
not report lipid outcomes.8 It will be important to determine whether the lipid advantages 
observed in the NRTI group translate into clinical benefit in persons with hyperlipidaemia or 
other major risk factors for coronary artery disease. We observed a shorter time to any grade 
3 or 4 toxicity (at least one grade higher than baseline) in the NRTI group (figure 4). 
SECOND-LINE reported more grade 3 and 4 adverse events in their NRTI group than in 
their raltegravir group, although overall adverse event rates were not different between 
groups. EARNEST observed no differences in grade 3 or 4 adverse events overall or those 
attributed to a study drug. In our study, no single type of toxicity predominated. This 
contrasts with the data from SECOND-LINE where gastrointestinal events were the 
predominant toxicity and were more common with NRTI use. Of note, zidovudine, a 
common cause of gastrointestinal adverse events, was used by 45% of the NRTI group in 
SECOND-LINE compared with 21% in our study (table 1). Types of adverse events in 
EARNEST were distributed among various categories. Cultural differences in self-reported 
signs and symptoms and varying assessment methods could explain the poor concordance of 
clinical adverse event rates among the three studies. Absence of a predominant NRTI-
associated toxicity profile across studies makes it difficult to suggest a specific population 
for whom ritonavir-boosted lopinavir plus raltegravir could offer short-term or long-term 
safety benefits. Similarly, we cannot address whether the difference in toxic effects would 
continue to favour the raltegravir group with longer-term follow-up, although long-term 
toxicities of NRTIs are of potential concern with therapies that might be taken for decades.
A strength of our study is that it was done at diverse sites in low-to-middle-income countries 
in Africa, Asia, and Latin America with little access to resistance testing, making it 
generalisable to settings where most people with HIV reside. One weakness of this study, 
SECOND-LINE, and EARNEST is that the open-label design might have led to bias in 
La Rosa et al. Page 11
Lancet HIV. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
assessment of symptoms and signs. However, our primary endpoint and several of our 
secondary endpoints were objective laboratory measurements on masked specimens. 
Adherence self-reporting might overestimate adherence and wording of adherence questions 
might influence responses (although we used a validated questionnaire that has been used 
previously in international studies). We could not assess adherence at baseline since 
participants could enter the study even if they had stopped antiretroviral medication after 
detection of first-line virological failure. Rates of AIDS-defining illnesses and serious toxic 
effects were low, making it more challenging to show differences between groups. 
Lipoatrophy, a side-effect of some NRTIs, was not assessed by quantitative methods, 
potentially attenuating our capacity to detect a difference between groups in terms of this 
side-effect.
In summary, A5273 adds clear and generalisable findings, which, in combination with 
EARNEST and SECOND-LINE, provide solid evidence to recommend ritonavir-boosted 
lopinavir plus NRTI or raltegravir for second-line antiretroviral therapy. Availability, cost, 
potential toxic effects, and plans for third-line antiretroviral therapy will be important 
determinants of the preferred strategy at the country level. Our data support the current 
WHO recommendation for a boosted protease inhibitor plus NRTIs as second-line HIV 
therapy after failing non-NRTI-based regimens in resource-limited settings, even when there 
is no access to resistance testing, irrespective of NRTI resistance. The high virological 
efficacy achieved in this setting suggests that health-care systems with limited resources 
might be best served by focusing on optimisation of drug availability and adherence, rather 
than resistance testing after first-line failure. The explanation for the observation that more 
extensive NRTI resistance at study entry was associated with better second line therapy 
outcome is under investigation.
 Acknowledgments
This study was supported National Institute of Allergy and Infectious Diseases (award number U01AI068636), 
National Institute of Mental Health (NIMH), and the National Institute of Dental and Craniofacial Research 
(NIDCR). The study was also funded via the following grants: AI069432, AI069438, AI069481, 2UM1AI069423 
(including a subcontract to the Pittsburgh Virology Specialty Laboratory), UM1 AI069471, and UM1 AI068634 
(ACTG Statistical and Data Management Center) and the Investigator-Initiated Studies Program of Merck Sharp & 
Dohme. The content is solely the responsibility of the authors and does not necessarily represent the official views 
of the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, or Merck Sharp & 
Dohme. Abbott Laboratories, Gilead Sciences, GlaxoSmithKline, and Merck Sharp & Dohme provided the study 
drugs. We thank the study participants, the other members of the A5273 team, especially Lara Hosey and Jennifer 
Rothenberg, and the staff members at the virology and genotyping laboratories for their work in testing for the 
primary endpoint and the genotyping. In addition, we thank Raphael J Landovitz for his support in reviewing all 
virological endpoints and the contributions of the staff at the sites and grants supporting their work, including grants 
UM1AI069423, UM1AI069423, UM1 AI069436, UM1 AI108568, UM1AI068636, AI069463, AI068638, 
AI069497, UM1AI069453, U01AI069484, UM1AI069518, UM1AI069417, UM1AI069476, 5UM1AI069399, and 
UM1 AI068636.
References
1. Granich R, Gupta S, Hersh B, et al. Trends in AIDS deaths, new infections and ART coverage in the 
top 30 countries with the highest AIDS mortality burden; 1990–2013. PLoS One. 2015; 
10:e0131353. [PubMed: 26147987] 
2. UNAIDS. “15 by 15” A Global Target Achieved. http://www.unaids.org/sites/default/files/
media_asset/UNAIDS_15by15_en.pdf (accessed Sept 8, 2015).
La Rosa et al. Page 12
Lancet HIV. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3. INSIGHT START Study Group. Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy 
in early asymptomatic HIV infection. N Engl J Med. 2015; 373:795–807. [PubMed: 26192873] 
4. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure 
prophylaxis for HIV. Sep. 2015 http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/ 
(accessed Oct 13, 2015).
5. Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral 
regimens for initial treatment of HIV-1: A randomized clinical trial in diverse multinational settings. 
PLoS Med. 2012; 9:e1001290. [PubMed: 22936892] 
6. Tilghman M, Tsai D, Buene TP, et al. Pooled nucleic acid testing to detect antiretroviral treatment 
failure in HIV-infected patients in Mozambique. J Acquir Immune Defic Syndr. 2015; 70:256–61. 
[PubMed: 26135327] 
7. World Health Organization. Forecasting demand for antiretrovirals: Preliminary analyses from the 
GPRM data adult formulations. Mar 23. 2015 http://www.who.int/hiv/amds/ARV-forecasting-
meeting-2015/en/ (accessed Sept 11, 2015).
8. Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV 
therapy in Africa. N Engl J Med. 2014; 371:234–47. [PubMed: 25014688] 
9. SECOND-LINE Study Group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse 
transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 
infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a 
randomized, open-label, non-inferiority study. Lancet. 2013; 381:2091–99. [PubMed: 23769235] 
10. Amin J, Boyd MA, Kumarasamy N, et al. Raltegravir non-inferior to nucleoside based regimens in 
second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the 
treatment of HIV-1 infection. PLoS One. 2015; 10:e0118228. [PubMed: 25723472] 
11. Chesney MA, Ickovic JR, Chambers DB, et al. Self-reported adherence to antiretroviral 
medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient 
Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS 
Clinical Trials Group (AACTG). AIDS Care. 2000; 12:255–66. [PubMed: 10928201] 
12. Division of AIDS. Toxicity scale. Dec. 2004 Version 1.0Clarification August 2009. http://rsc.tech-
res.com/safetyandpharmacovigilance/gradingtables.aspx (accessed April 14, 2015)
13. Centers for Disease Control. Revised classification system for HIV infection and expanded 
surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly 
Rep. 1993; 1992; 41:17.
14. WHO. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for 
surveillance. Geneva: World Health Organization; 2005. WHO/HIV/2005.02
15. Appendix 60. http://www.hptn.org/web20documents/HPTN052/Appendix60V1.123Feb2007.pdf 
(accessed Sept 11, 2015).
16. Wensing AM, Calvez V, Gü nthard HF, et al. 2014 Update of the drug resistance mutations in 
HIV-1. Top Antivir Med. 2014; 22:642–50. [PubMed: 25101529] 
17. Stanford Genotypic Resistance Interpretation Algorithm. Version 7. 0 (last updated 02/27/14). 
http://sierra2.stanford.edu/sierra/servlet/JSierra (accessed Sept 11, 2015).
18. Gross R, Zheng L, La Rosa A, et al. Partner-focused adherence intervention for second-line 
antiretroviral therapy: a multinational randomized trial (ACTG A5234). Lancet HIV. 2015; 2:e12–
19.
19. Greenwood, M. Reports on Public Health and Medical Subjects. Vol. 33. London: HM Stationery 
Office; 1926. The natural duration of cancer; p. 1-26.
20. Prentice RL, Kalbfleisch JD. Hazard rate models with covariates. Biometrics. 1979; 35:25–39. 
[PubMed: 497336] 
21. Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional 
antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS. 
2007; 21:1405–14. [PubMed: 17589186] 
22. Boyd MA, Moore CL, Molina J-M, et al. Baseline HIV-1 resistance, virological outcomes, and 
emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV. 2015; 
2:e42–51. [PubMed: 26424460] 
La Rosa et al. Page 13
Lancet HIV. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
23. Paton, N.; Kityo, C.; Thompson, J., et al. Impact of NRTI cross-resistance on second-line PI + 
NRTI therapy outcomes in Africa; Conference on Retrovirus and Opportunistic Infections; Seattle, 
WA, USA. Feb 23–26, 2015; 2015. 119 (abstr)
24. Kumarasamy N, Aga E, Ribaudo HJ, et al. Lopinavir/ritonavir monotherapy as second-line 
antiretroviral treatment in resource-limited settings: week 104 analysis of AIDS Clinical Trials 
Group (ACTG) A5230. Clin Infect Dis. 2015; 60:1552–58. [PubMed: 25694653] 
25. Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA. Diminished efficiency of HIV-1 reverse 
transcriptase containing the K65R and M184V drug resistance mutations. AIDS. 2007; 21(6):665–
75. [PubMed: 17413687] 
26. Martinez-Picado J, Wrin T, Frost SD, et al. Phenotypic hypersusceptibility to multiple protease 
inhibitors and low replicative capacity in patients who are chronically infected with human 
immunodeficiency virus type 1. J Virol. 2005; 79:55907–13.
27. Rabi SA, Laird GM, Durand CM, et al. Multi-step inhibition explains HIV-1 protease inhibitor 
pharmacodynamics and resistance. J Clin Invest. 2013; 123:3848–60. [PubMed: 23979165] 
28. Moyle GJ, Orkin C, Fisher M, et al. A randomized comparative trial of continued abacavir/
lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in 
hypercholesterolemic HIV-1 infected individuals. PLoS One. 2015; 10:e0116297. [PubMed: 
25658097] 
29. Souza SJ, Luzia LA, Santos SS, Rondó PH. Lipid profile of HIV-infected patients in relation to 
antiretroviral therapy: a review. Rev Assoc Med Bras. 2013; 59:186–98. [PubMed: 23582562] 
La Rosa et al. Page 14
Lancet HIV. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Research in context
Evidence before this study
After failure of first-line regimens consisting of a non-nucleoside reverse transcriptase 
inhibitor plus two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) in 
resource-limited settings, second-line regimens are generally selected without resistance 
testing and few different drugs are generally available. Thus, NRTIs might have cross-
resistance to those used in initial therapy, which could potentially result in less effective 
second-line therapy. When this study was being planned, no adequately powered, 
randomised studies had been completed in resource-limited settings to compare an NRTI-
sparing regimen with the WHO-recommended second-line regimen of a boosted protease 
inhibitor plus NRTIs. We were aware of two planned and subsequently completed 
studies. EARNEST was a three-group study that compared ritonavir-boosted lopinavir 
plus NRTIs, ritonavir-boosted lopinavir plus raltegravir, and ritonavir-boosted lopinavir 
monotherapy in five sub-Saharan African countries with a composite endpoint of good 
disease control and without resistance testing to guide NRTI selection. SECOND-LINE 
assessed the same two combination regimens in middle-income and high-income 
countries with a pure virological endpoint and three-quarters of the NRTIs selected with 
resistance-testing results. In EARNEST, ritonavir-boosted lopinavir monotherapy was 
inferior. However, both EARNEST and SECOND-LINE showed ritonavir-boosted 
lopinavir plus raltegravir to be non-inferior and not superior to ritonavir-boosted lopinavir 
plus NRTIs, and pronounced these two regimens as viable alternatives for second-line 
therapy in resource-limited settings. We searched PubMed for papers published in 
English and Spanish with no date restrictions in September and October, 2015, using 
terms that included “secondline and HIV” or “secondline and antiretroviral” and 
“randomized clinical trial”. We also read the references of US and WHO antiretroviral 
therapy guidelines and the abstracts of major HIV research meetings, including the 
Conference on Retroviruses and Opportunistic Infections, International AIDS 
Conferences, and International AIDS Society Meetings for the previous 4 years, and 
asked all of the masthead authors for relevant research for this manuscript.
Added value of this study
Results from this, the AIDS Clinical Trials Group (ACTG) A5273 SELECT study, 
confirms findings from EARNEST and SECOND-LINE and expands the breadth of 
evidence by providing data from a robust clinical trial in nine low-income and middle-
income countries in Africa, Asia, and South America where resistance testing is not 
generally used for selection of second-line antiretroviral therapy (96% of our participants 
enrolled did not have access to resistance tests). Our findings support current WHO 
guidance for second-line therapy in resource-limited settings.
Implications of all the available evidence
The evidence indicates that ritonavir-boosted lopinavir plus NRTIs and ritonavir-boosted 
lopinavir plus raltegravir are both acceptable options for second-line antiretroviral 
treatment in resource-limited settings. Although concern about cross-resistance has been 
a major driver of interest in NRTI-sparing options for settings without resistance-testing 
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capacity, evidence has accumulated showing that efficacy of ritonavir-boosted lopinavir 
plus NRTI for second-line ART in resource-limited settings is not significantly 
compromised by previous NRTI resistance. Accordingly, drug availability, cost, and 
potential toxic effects should drive decisions about which strategy to prioritise over others 
at the country level.
Here we report results of AIDS Clinical Trials Group (ACTG) A5273, the Second-Line 
Effective Combination Therapy (SELECT) study; which was done exclusively in low-
income and middle-income countries in Africa, Asia, and Latin America without use of 
genotyping to select NRTIs. We hypothesised that the combination of ritonavir-boosted 
lopinavir plus raltegravir is non-inferior to one of ritonavir-boosted lopinavir plus the 
best-available NRTIs.
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Figure 1. Trial profile
LPV/r=ritonavir-boosted lopinavir. NRTI=nucleoside or nucleotide reverse transcriptase 
inhibitor.
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Figure 2. Cumulative probability of virological failure
Time is weeks since study entry. LPV/r=ritonavir-boosted lopinavir.
NRTI=nucleoside or nucleotide reverse transcriptase inhibitor.
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Figure 3. Difference in the cumulative probability of virological failure at week 48 between 
groups for prespecified subgroups
LPV/r=ritonavir-boosted lopinavir. NRTI=nucleoside or nucleotide reverse transcriptase 
inhibitors. ZDV=zidovudine.
IAS=International AIDS Society. The dotted line represents the prespecified non-inferiority 
margin.
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Figure 4. Cumulative probability of an adverse event
Includes all participants who started randomised study drug; time is weeks since first dose of 
study treatment. LPV/r=ritonavir-boosted lopinavir.
NRTI=nucleoside or nucleotide reverse transcriptase inhibitors.
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Table 1
Baseline characteristics
Raltegravir group (n=258) NRTI group (n=254)
Age (years)   39 (34–44)   38 (33–43)
Men 124 (48%) 128 (50%)
Race
 White, non-Hispanic     0     1 (<1%)
 Black, non-Hispanic 164 (64%) 162 (64%)
 Hispanic   11 (4%)     9 (4%)
 Asian or Pacific Islander   83 (32%)   82 (32%)
Body-mass index (kg/m2)   23 (20–27)   22 (19–25)
Plasma HIV-1 RNA
 Log10 copies per mL     4·6 (0·8)     4·5 (0·9)
 ≥100 000 copies per mL at screening   84 (33%)   82 (32%)
CD4 counts (cells per μL) 178 (170) 182 (160)
Nadir CD4 counts (cell per μL) 122 (136) 113 (96)
Time on first-line regimen (years)     4·1 (2·2–6·3)     4·0 (2·2–6·0)
Past AIDS-defining event   70 (27%)   80 (31%)
HIV-1 subtype*
 A1   21/244 (9%)   26/246 (11%)
 B   10/244 (4%)     8/246 (3%)
 C 201/244 (82%) 195/246 (79%)
 Other   12/244 (5%)   17/246 (7%)
NRTI selected for use at study entry†
 Emtricitabine and tenofovir‡     – 173 (68%)
 Lamivudine and zidovudine     –   49 (19%)
 Lamivudine and abacavir     –   21 (8%)
 Emtricitabine, tenofovir‡, and zidovudine     –     8 (3%)
 Lamivudine, zidovudine, and abacavir     –     2 (1%)
Local resistance test available before study entry   10 (4%)     9 (4%)
Genotypic mutations at baseline§ 244 (95%) 246 (97%)†
 At least one NRTI mutation 231/244 (95%) 238/246 (97%)
  Met184Val/Ile 217/244 (89%) 221/246 (90%)
  Lys65Arg   56/244 (23%)   51/246 (21%)
  ≥1 TAM 113/244 (46%) 124/246 (50%)
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Raltegravir group (n=258) NRTI group (n=254)
  ≥3 TAMs   59/244 (24%)   60/246 (24%)
  Gln151Met     3/244 (1%)     7/246 (3%)
  69 insertion/deletion     0     4/246 (2%)
  Complex resistance (Lys65Arg, ≥3 TAMs, Gln151Met, 69 insertion/deletion) 115/244 (47%) 119/246 (48%)
  NRTI genotypic sensitivity score†
  <1     – 117/245 (48%)
  ≥1     – 128/245 (52%)
≥1 NNRTI mutation 238/244 (98%) 238/246 (97%)
Data are median (IQR), n (%), mean (SD), or n/N (%). NRTI=nucleoside or nucleotide reverse transcriptase inhibitor. NNRTI=non-nucleoside/
nucleotide reverse transcriptase inhibitor. TAM=thymidine analogue mutation.
*
HIV subtype for 490 participants with HIV resistance tests at study entry.
†One participant did not start treatment in NRTI arm.
‡
Tenofovir disoproxil fumarate.
§Codon mixtures are counted as mutant.
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Table 2
HIV resistance testing at virological failure
Raltegravir group (n=46) NRTI group* (n=50)
Any mutation† 39 (85%) 45 (90%)
 New NRTI mutations
  Met184Val/Ile   1/39 (3%)   1/45 (2%)
  Lys65Arg   0   0
  TAMS   0   4/45 (9%)
  Gln151Met   0   0
  Thr69Asn   0   1/45 (2%)
 Major protease inhibitor mutations
  Met46Ile   0   3/45 (7%)
  Leu76Val   0   2/45(4%)
  Val82Ala   0   2/45(4%)
 Integrase mutations
  Thr66Ala   1/39 (3%)   0
  Thr97Ala   3/39 (8%)   0
  Tyr143Cys/Arg   2/39 (5%)   0
  Asn155His   6/39 (15%)   0
Codon mixtures are counted as mutant. NRTI=nucleoside reverse transcriptase inhibitor. TAM=thymidine analogue mutation.
*Not available for one participant who did not start treatment in NRTI arm.
†Number of participants with paired study entry and failure genotypes.
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Table 3
Grade 3 or 4 adverse events, deaths, AIDS-defining events, non-AIDS-defining events, and hospitalisations
Raltegravir group (n=258) NRTI group (n=254)
Clinical adverse events   27   46
 Participants with at least one event   18 (7%)   27 (11%)
  General body   10 (4%)   15 (6%)
   Pain     5 (2%)     5 (2%)
   Cachexia     4 (2%)     5 (2%)
   Asthenia, fatigue, or malaise     0 (0%)     2 (1%)
   Fever     1 (<0·5%)     4 (2%)
 Circulatory or cardiac     1 (<0·5%)     0
 Haematology     2 (1%)     0
 Gastrointestinal     6 (2%)     7 (3%)
  Diarrhoeal     6 (2%)     7 (3%)
 Skin     0     1 (<0·5%)
 Neurological     1 (<0·5%)     7 (3%)
 Special senses     0     1 (<0·5%)
 Other     0     2 (1%)
 Multiple attribution     1 (<0·5%)     2 (1%)
Laboratory adverse events 185 197
 Participants with at least one event(%)   62 (24%)   71 (28%)
 Chemistry   18 (7%)   35 (14%)
  Low albumin     1 (<0·5%)     0
  High alkaline phosphatase     1 (<0·5%)     1 (<0·5%)
  Low bicarbonate     2 (1%)     0
  High or low calcium     2 (1%)     0
  High carbon dioxide     0     1 (<0·5%)
  Low phosphorus   11 (4%)   23 (9%)
  High or low potassium     3 (1%)     6 (2%)
  High or low sodium     4 (2%)     7 (3%)
 Haematology     9 (3%)   14 (6%)
  Low absolute neutrophil count     3 (1%)     7 (3%)
  Low haemoglobin     1 (<0·5%)     6 (2%)
  Low platelets     5 (2%)     3 (1%)
  Low white blood cells     0     2 (1%)
 Hepatic     8 (3%)     6 (2%)
 Metabolic   38 (15%)   23 (9%)
  High fasting LDL cholesterol   17 (7%)     6 (2%)
  High fasting total cholesterol   18 (7%)   10 (4%)
  High fasting triglycerides   12 (5%)   13 (5%)
  High non-fasting glucose     3 (1%)     1 (<0·5%)
  Endocrine     3 (1%)     5 (2%)
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Raltegravir group (n=258) NRTI group (n=254)
  Pancreatic     0     1 (<0·5%)
  Renal     3 (1%)     3 (1%)
  Urinalysis     0     2 (1%)
  Any*   62 (24%)   81 (32%)
 Events
  Deaths†     3     3
  AIDS-defining illnesses   13 (n=12)   14 (n=14)
   Bacterial pneumonia‡     1     1
   Cervical cancer     0     1
   Cryptococcal meningitis     0     1
   Herpes simplex virus disease§     1     1
   HIV-associated dementia     1     0
   Tuberculosis   10   10
  Number of serious non-AIDS-defining events¶     6 (n=5)     5 (n=5)
   Acute gastrointestinal or diarrhoeal syndrome     0     1
   Bacterial sepsis     3     0
   Cerebrovascular accident (stroke)     0     1
   Acute myocardial infarction     1     0
   Deep-vein thrombosis     1     0
   Depression     0     1
   Genitourinary and renal system disease or disorder     1     2
  Number of hospitalisations   16 (6%)   23 (9%)
   Incidence (per 100 person-years)     5·2     8·3
Adverse events do not add to the total of the category since participants can have multiple events across categories. NRTI=nucleoside or nucleotide 
reverse transcriptase inhibitors.
*
These events also had to be at least one grade higher than baseline and occur while on randomised therapy.
†All deaths were considered HIV-related; primary causes of death were tuberculosis, sepsis, Kaposi’s sarcoma, acute respiratory failure, acute 
gastroenteritis, and stroke.
‡
Two separate episodes of bacterial pneumonia within 12 months.
§
Herpes simplex virus lesions persisting longer than 30 days.
¶
To be considered serious, these events had to either result in hospitalisation or be of moderate or higher severity.
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